Research Grants in Prematurity & Preeclampsia
AMAG Pharmaceuticals, Inc. is committed to funding research aimed at reducing the risk of premature birth and preeclampsia in order to improve the health of neonates and infants in the United States through its Prematurity and Preeclampsia Research Grants Program. Consideration will be given to basic or clinical research in maternal, fetal and neonatal/infant health.
1 year
Upper $50,000USD
The company is pleased to announce that it will be funding research grants in prematurity and preeclampsia in 2020 for a total of $250,000. The panel will determine allocation of these funds, with no single recipient receiving more than $50,000 to allow for multiple grants to be provided.
Early career investigators, including community-based clinicians, investigators in-training, as well as basic scientists, are encouraged to submit their research proposals for consideration.